{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:55:17Z","timestamp":1790834117934,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,6,24]],"date-time":"2018-06-24T00:00:00Z","timestamp":1529798400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00228-018-2505-6","type":"journal-article","created":{"date-parts":[[2018,6,24]],"date-time":"2018-06-24T06:23:10Z","timestamp":1529821390000},"page":"1291-1298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Association of CYP2C19*2 and ALDH1A1*1\/*2 variants with disease outcome in breast cancer patients: results of a global screening array"],"prefix":"10.1007","volume":"74","author":[{"given":"Sourav","family":"Kalra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman Preet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhilash","family":"Ludhiadch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowhar","family":"Shafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Vashista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,24]]},"reference":[{"key":"2505_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87\u2013108","journal-title":"CA Cancer J Clin"},{"key":"2505_CR2","doi-asserted-by":"crossref","unstructured":"Stewart B, Wild C (2014) World cancer report 2014. 2014. Lyon CEDEX, France","DOI":"10.12968\/nuwa.2014.10.2.1142051"},{"key":"2505_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3322\/caac.21203","volume":"64","author":"C DeSantis","year":"2014","unstructured":"DeSantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64:52\u201362","journal-title":"CA Cancer J Clin"},{"key":"2505_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S13139","volume":"4","author":"A Collins","year":"2011","unstructured":"Collins A, Politopoulos I (2011) The genetics of breast cancer: risk factors for disease. Appl Clin Genet 4:11","journal-title":"Appl Clin Genet"},{"key":"2505_CR5","first-page":"14","volume":"8","author":"C Brezden-Masley","year":"2005","unstructured":"Brezden-Masley C, Trudeau M (2005) Treatment strategies for breast cancer. Geriatrics Aging 8:14","journal-title":"Geriatrics Aging"},{"key":"2505_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3892\/or_00000963","volume":"24","author":"M Hassan","year":"2010","unstructured":"Hassan M, Ansari J, Spooner D, Hussain S (2010) Chemotherapy for breast cancer. Oncol Rep 24:1121\u20131131","journal-title":"Oncol Rep"},{"key":"2505_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/sj.bjc.6605587","volume":"102","author":"J Bray","year":"2010","unstructured":"Bray J, Sludden J, Griffin M, Cole M, Verrill M, Jamieson D, Boddy A (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 102:1003","journal-title":"Br J Cancer"},{"key":"2505_CR8","first-page":"298","volume":"14","author":"S Ahmed","year":"2016","unstructured":"Ahmed S, Zhou Z, Zhou J, Chen S-Q (2016) Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics. Proteomics Bioinformatics 14:298\u2013313","journal-title":"Proteomics Bioinformatics"},{"key":"2505_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40262-016-0450-z","volume":"56","author":"D Bertholee","year":"2017","unstructured":"Bertholee D, Maring JG, van Kuilenburg AB (2017) Genotypes affecting the pharmacokinetics of anticancer drugs. Clin Pharmacokinet 56:317\u2013337","journal-title":"Clin Pharmacokinet"},{"key":"2505_CR10","unstructured":"Hicks JK, McLeod HL (2017) Pharmacogenetics and Pharmacogenomics. In: Genomic and Precision Medicine (Third Edition). Elsevier, 89\u2013107"},{"key":"2505_CR11","doi-asserted-by":"publisher","first-page":"10531","DOI":"10.1093\/nar\/15.24.10531","volume":"15","author":"KW Kohn","year":"1987","unstructured":"Kohn KW, Hartley JA, Mattes WB (1987) Mechanisms of DNA sequence selective alkylation of guanine-N7 positions by nitrogen mustards. Nucleic Acids Res 15:10531\u201310549","journal-title":"Nucleic Acids Res"},{"key":"2505_CR12","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.dnarep.2004.05.004","volume":"3","author":"F Drabl\u00f8s","year":"2004","unstructured":"Drabl\u00f8s F, Feyzi E, Aas PA, Vaagb\u00f8 CB, Kavli B, Bratlie MS, Pe\u00f1a-Diaz J, Otterlei M, Slupphaug G, Krokan HE (2004) Alkylation damage in DNA and RNA\u2014repair mechanisms and medical significance. DNA Repair 3:1389\u20131407","journal-title":"DNA Repair"},{"key":"2505_CR13","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/art.20338","volume":"50","author":"K Takada","year":"2004","unstructured":"Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG (2004) Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 50:2202\u20132210","journal-title":"Arthritis Rheum"},{"key":"2505_CR14","first-page":"5629","volume":"53","author":"TK Chang","year":"1993","unstructured":"Chang TK, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629\u20135637","journal-title":"Cancer Res"},{"key":"2505_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/leu.2008.323","volume":"23","author":"V Rocha","year":"2009","unstructured":"Rocha V, Porcher R, Fernandes J, Filion A, Bittencourt H, Silva W, Vilela G, Zanette D, Ferry C, Larghero J (2009) Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 23:545\u2013556","journal-title":"Leukemia"},{"key":"2505_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.fertnstert.2009.03.034","volume":"94","author":"HI Su","year":"2010","unstructured":"Su HI, Sammel MD, Velders L, Horn M, Stankiewicz C, Matro J, Gracia CR, Green J, DeMichele A (2010) Association of cyclophosphamide drug\u2013metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertil Steril 94:645\u2013654","journal-title":"Fertil Steril"},{"key":"2505_CR17","doi-asserted-by":"publisher","first-page":"6117","DOI":"10.1200\/JCO.2005.06.075","volume":"23","author":"WP Petros","year":"2005","unstructured":"Petros WP, Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM, Peters WP, Jones RB, Hall J, Marks JR (2005) Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 23:6117\u20136125","journal-title":"J Clin Oncol"},{"key":"2505_CR18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.4238\/vol9-2gmr726","volume":"9","author":"A Oliveira","year":"2010","unstructured":"Oliveira A, Rodrigues F, Santos R, Aoki T, Rocha M, Longui C, Melo M (2010) GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genet Mol Res 9:1045\u20131053","journal-title":"Genet Mol Res"},{"key":"2505_CR19","first-page":"199","volume":"124","author":"B Zhang","year":"2011","unstructured":"Zhang B, Sun T, Zhang B, Zheng S, L\u00fc N, Xu B, Wang X, Chen G, Yu D, Lin D (2011) Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chin Med J 124:199\u2013204","journal-title":"Chin Med J"},{"key":"2505_CR20","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s10552-013-0237-6","volume":"24","author":"JD Brooks","year":"2013","unstructured":"Brooks JD, Teraoka SN, Bernstein L, Mellemkj\u00e6r L, Malone KE, Lynch CF, Haile RW, Concannon P, Reiner AS, Duggan DJ (2013) Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case\u2013control study of contralateral breast cancer risk in the WECARE study. Cancer Causes Control 24:1605\u20131614","journal-title":"Cancer Causes Control"},{"key":"2505_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s12282-014-0547-x","volume":"23","author":"M Sugishita","year":"2016","unstructured":"Sugishita M, Imai T, Kikumori T, Mitsuma A, Shimokata T, Shibata T, Morita S, Inada-Inoue M, Sawaki M, Hasegawa Y (2016) Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer. Breast Cancer 23:195\u2013201","journal-title":"Breast Cancer"},{"key":"2505_CR22","doi-asserted-by":"publisher","first-page":"e26091","DOI":"10.1371\/journal.pone.0026091","volume":"6","author":"D Caronia","year":"2011","unstructured":"Caronia D, Patino-Garcia A, Per\u00e9z-Mart\u00ednez A, Pita G, Moreno LT, Zalacain-D\u00edez M, Molina B, Colmenero I, Sierrases\u00famaga L, Ben\u00edtez J (2011) Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One 6:e26091","journal-title":"PLoS One"},{"key":"2505_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fphar.2018.00158","volume":"9","author":"B Bidadi","year":"2018","unstructured":"Bidadi B, Liu D, Kalari KR, Rubner M, Hein A, Beckmann MW, Rack B, Janni W, Fasching PA, Weinshilboum RM (2018) Pathway-based analysis of genome-wide association data identified SNPs in HMMR as biomarker for chemotherapy-induced neutropenia in breast Cancer patients. Front Pharmacol 9:158","journal-title":"Front Pharmacol"},{"key":"2505_CR24","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/ijc.10896","volume":"103","author":"C Sweeney","year":"2003","unstructured":"Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, Kadlubar FF, Coles BF (2003) Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 103:810\u2013814","journal-title":"Int J Cancer"},{"key":"2505_CR25","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1158\/1078-0432.CCR-09-0685","volume":"15","author":"J-Y Choi","year":"2009","unstructured":"Choi J-Y, Barlow WE, Albain KS, Hong C-C, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh I-T, Hutchins LF (2009) Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a southwest oncology group clinical trial. Clin Cancer Res 15:5258\u20135266","journal-title":"Clin Cancer Res"},{"key":"2505_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/bcp.12800","volume":"81","author":"W Shu","year":"2016","unstructured":"Shu W, Guan S, Yang X, Liang L, Li J, Chen Z, Zhang Y, Chen L, Wang X, Huang M (2016) Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide\u2019s 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus. Br J Clin Pharmacol 81:327\u2013340","journal-title":"Br J Clin Pharmacol"},{"key":"2505_CR27","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/FPC.0b013e32834b6918","volume":"21","author":"D Jamieson","year":"2011","unstructured":"Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EV, Verrill MW, May FE (2011) Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenet Genomics 21:808\u2013819","journal-title":"Pharmacogenet Genomics"},{"key":"2505_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2217\/pgs.11.140","volume":"13","author":"A Khrunin","year":"2012","unstructured":"Khrunin A, Ivanova F, Moisseev A, Khokhrin D, Sleptsova Y, Gorbunova V, Limborska S (2012) Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics 13:171\u2013178","journal-title":"Pharmacogenomics"},{"key":"2505_CR29","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/FPC.0b013e328313aaa4","volume":"18","author":"C Ekhart","year":"2008","unstructured":"Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD (2008) Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacog Genomics 18:1009\u20131015","journal-title":"Pharmacog Genomics"},{"key":"2505_CR30","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1634\/theoncologist.2010-0259","volume":"16","author":"MJ Deenen","year":"2011","unstructured":"Deenen MJ, Cats A, Beijnen JH, Schellens JH (2011) Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist 16:820\u2013834","journal-title":"Oncologist"},{"key":"2505_CR31","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/0006-2952(93)90669-N","volume":"46","author":"HK Parekh","year":"1993","unstructured":"Parekh HK, Sladek NE (1993) NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide. Biochem Pharmacol 46:1043\u20131052","journal-title":"Biochem Pharmacol"},{"key":"2505_CR32","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2217\/pgs.09.134","volume":"10","author":"N Pinto","year":"2009","unstructured":"Pinto N, Ludeman SM, Dolan ME (2009) Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 10:1897\u20131903","journal-title":"Pharmacogenomics"},{"key":"2505_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev.pharmtox.45.120403.095857","volume":"45","author":"JD Hayes","year":"2005","unstructured":"Hayes JD, Flanagan JU, Jowsey IR (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51\u201388","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2505_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0169-409X(97)00029-X","volume":"26","author":"M Schultz","year":"1997","unstructured":"Schultz M, Dutta S, Tew KD (1997) Inhibitors of glutathione S-transferases as therapeutic agents. Adv Drug Del Rev 26:91\u2013104","journal-title":"Adv Drug Del Rev"},{"key":"2505_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","volume":"7","author":"H Cort\u00e9s-Funes","year":"2007","unstructured":"Cort\u00e9s-Funes H, Coronado C (2007) Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 7:56\u201360","journal-title":"Cardiovasc Toxicol"},{"key":"2505_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","volume":"57","author":"D Gewirtz","year":"1999","unstructured":"Gewirtz D (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 57:727\u2013741","journal-title":"Biochem Pharmacol"},{"key":"2505_CR37","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1349-7006.2008.00744.x","volume":"99","author":"S Lal","year":"2008","unstructured":"Lal S, Wong ZW, Sandanaraj E, Xiang X, Ang PCS, Lee EJ, Chowbay B (2008) Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99:816\u2013823","journal-title":"Cancer Sci"},{"key":"2505_CR38","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1371\/journal.pgen.0030039","volume":"3","author":"H Jeong","year":"2007","unstructured":"Jeong H, Herskowitz I, Kroetz DL, Rine J (2007) Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a saccharomyces-based assay. PLoS Genet 3:e39","journal-title":"PLoS Genet"},{"key":"2505_CR39","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","volume":"112","author":"L Wojnowski","year":"2005","unstructured":"Wojnowski L, Kulle B, Schirmer M, Schl\u00fcter G, Schmidt A, Rosenberger A, Vonhof S, Bickeb\u00f6ller H, Toliat MR, Suk E-K (2005) NAD (P) H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754\u20133762","journal-title":"Circulation"},{"key":"2505_CR40","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s100380170017","volume":"46","author":"S Conrad","year":"2001","unstructured":"Conrad S, Kauffmann H-M, Ito K-I, Deeley RG, Cole SP, Schrenk D (2001) Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 46:656\u2013663","journal-title":"J Hum Genet"},{"key":"2505_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00008571-200206000-00008","volume":"12","author":"S Conrad","year":"2002","unstructured":"Conrad S, Kauffmann H-M, Ito K-i, Leslie EM, Deeley RG, Schrenk D, Cole SP (2002) A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenet Genomics 12:321\u2013330","journal-title":"Pharmacogenet Genomics"},{"key":"2505_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/FPC.0b013e328323f680","volume":"19","author":"J-Y Yin","year":"2009","unstructured":"Yin J-Y, Huang Q, Yang Y, Zhang J-T, Zhong M-Z, Zhou H-H, Liu Z-Q (2009) Characterization and analyses of multidrug resistance-associated protein 1 (MRP1\/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 19:206","journal-title":"Pharmacogenet Genomics"},{"key":"2505_CR43","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1124\/dmd.108.024711","volume":"37","author":"OS Bains","year":"2009","unstructured":"Bains OS, Karkling MJ, Grigliatti TA, Reid RE, Riggs KW (2009) Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Disposition 37:1107\u20131114","journal-title":"Drug Metab Disposition"},{"key":"2505_CR44","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1111\/j.1349-7006.2008.00744.x","volume":"99","author":"S Lal","year":"2008","unstructured":"Lal S, Sandanaraj E, Wong ZW, Ang P, Wong NS, Lee EJ, Chowbay B (2008) CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99:2045\u20132054","journal-title":"Cancer Sci"},{"key":"2505_CR45","unstructured":"Singh BP (2008) Cancer Deaths in Agricultural Heartland A Study in Malwa Region of Indian Punjab"},{"key":"2505_CR46","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.scitotenv.2013.06.066","volume":"463","author":"J Bedi","year":"2013","unstructured":"Bedi J, Gill J, Aulakh R, Kaur P, Sharma A, Pooni P (2013) Pesticide residues in human breast milk: risk assessment for infants from Punjab. India Sci Total Environ 463:720\u2013726","journal-title":"India Sci Total Environ"},{"key":"2505_CR47","first-page":"1","volume":"8","author":"E Blaurock-Busch","year":"2014","unstructured":"Blaurock-Busch E, Busch YM, Friedle A, Buerner H, Parkash C, Kaur A (2014) Comparing the metal concentration in the hair of cancer patients and healthy people living in the Malwa region of Punjab. India Clin Med Insights Oncol 8:1\u201313","journal-title":"India Clin Med Insights Oncol"},{"key":"2505_CR48","first-page":"56","volume":"8","author":"I Ali","year":"2011","unstructured":"Ali I, Wani WA, Saleem K (2011) Cancer scenario in India with future perspectives. Cancer Ther 8:56\u201370","journal-title":"Cancer Ther"},{"key":"2505_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","volume":"12","author":"JK Lamba","year":"2002","unstructured":"Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenet Genomics 12:121\u2013132","journal-title":"Pharmacogenet Genomics"},{"key":"2505_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sj.tpj.6500144","volume":"3","author":"D Flockhart","year":"2003","unstructured":"Flockhart D, Rae J (2003) Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenomics J 3:3\u20135","journal-title":"Pharmacogenomics J"},{"key":"2505_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","volume":"11","author":"T Lang","year":"2001","unstructured":"Lang T, Klein K, Fischer J, N\u00fcssler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenet Genomics 11:399\u2013415","journal-title":"Pharmacogenet Genomics"},{"key":"2505_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cca.2014.04.009","volume":"434","author":"S Tulsyan","year":"2014","unstructured":"Tulsyan S, Agarwal G, Lal P, Mittal B (2014) Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy. Clin Chim Acta 434:21\u201328","journal-title":"Clin Chim Acta"},{"key":"2505_CR53","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S0006-2952(99)00410-4","volume":"59","author":"Z Huang","year":"2000","unstructured":"Huang Z, Roy P, Waxman DJ (2000) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59:961\u2013972","journal-title":"Biochem Pharmacol"},{"key":"2505_CR54","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2217\/pgs-2017-0069","volume":"18","author":"K Kumaraswami","year":"2017","unstructured":"Kumaraswami K, Katkam SK, Aggarwal A, Sharma A, Manthri R, Kutala VK, Rajasekhar L (2017) Epistatic interactions among CYP2C19* 2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients. Pharmacogenomics 18:1401\u20131411","journal-title":"Pharmacogenomics"},{"key":"2505_CR55","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00296-010-1420-7","volume":"31","author":"P Ngamjanyaporn","year":"2011","unstructured":"Ngamjanyaporn P, Thakkinstian A, Verasertniyom O, Chatchaipun P, Vanichapuntu M, Nantiruj K, Totemchokchyakarn K, Attia J, Janwityanujit S (2011) Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus. Rheumatol Int 31:1215\u20131218","journal-title":"Rheumatol Int"},{"key":"2505_CR56","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.clim.2015.07.010","volume":"160","author":"H-N Wang","year":"2015","unstructured":"Wang H-N, Zhu X-Y, Zhu Y, Xie Q-H, Lai L-Y, Zhao M, Chen Y-C, Xue J, Hao C-M, Gu Y (2015) The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients. Clin Immunol 160:342\u2013348","journal-title":"Clin Immunol"},{"key":"2505_CR57","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00280-001-0412-4","volume":"49","author":"NE Sl\u00e1dek","year":"2002","unstructured":"Sl\u00e1dek NE, Kollander R, Sreerama L, Kiang DT (2002) Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Cancer Chemother Pharmacol 49:309\u2013321","journal-title":"Cancer Chemother Pharmacol"},{"key":"2505_CR58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1079\/PNS2003327","volume":"63","author":"DW Crabb","year":"2004","unstructured":"Crabb DW, Matsumoto M, Chang D, You M (2004) Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc 63:49\u201363","journal-title":"Proc Nutr Soc"},{"key":"2505_CR59","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1530-0277.2010.01346.x","volume":"35","author":"J Liu","year":"2011","unstructured":"Liu J, Zhou Z, Hodgkinson CA, Yuan Q, Shen PH, Mulligan CJ, Wang A, Gray RR, Roy A, Virkkunen M (2011) Haplotype-based study of the association of alcohol-metabolizing genes with alcohol dependence in four independent populations. Alcohol Clin Exp Res 35:304\u2013316","journal-title":"Alcohol Clin Exp Res"},{"key":"2505_CR60","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1097\/01.ALC.0000087086.50089.59","volume":"27","author":"JP Spence","year":"2003","unstructured":"Spence JP, Liang T, Eriksson C, Taylor RE, Wall TL, Ehlers CL, Carr LG (2003) Evaluation of aldehyde dehydrogenase 1 promoter polymorphisms identified in human populations. Alcohol Clin Exp Res 27:1389\u20131394","journal-title":"Alcohol Clin Exp Res"},{"key":"2505_CR61","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/FPC.0b013e3282fc9766","volume":"18","author":"C Ekhart","year":"2008","unstructured":"Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD (2008) Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 18:515\u2013523","journal-title":"Pharmacogenet Genomics"},{"key":"2505_CR62","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/1471-2407-14-444","volume":"14","author":"Y Liu","year":"2014","unstructured":"Liu Y, Lv D-L, Duan J-J, Xu S-L, Zhang J-F, Yang X-J, Zhang X, Cui Y-H, Bian X-W, Yu S-C (2014) ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis. BMC Cancer 14:444","journal-title":"BMC Cancer"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2505-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2505-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2505-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T23:11:52Z","timestamp":1561331512000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2505-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,24]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["2505"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2505-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,24]]},"assertion":[{"value":"8 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}